Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

SIMPLE SUMMARY: Only 10–20% of patients with newly diagnosed resectable pancreatic adenocarcinoma have potentially resectable disease. Upfront surgery is the gold standard, but it is rarely curative. After surgical extirpation of tumors, up to 80% of patients will develop cancer recurrence, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Aurélien, Schwarz, Lilian, Ducreux, Michel, Conroy, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469083/
https://www.ncbi.nlm.nih.gov/pubmed/34572951
http://dx.doi.org/10.3390/cancers13184724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469083/
https://www.ncbi.nlm.nih.gov/pubmed/34572951
http://dx.doi.org/10.3390/cancers13184724

Ejemplares similares